AbbVie Company Press-Release

DOI:

https://doi.org/10.21320/
AbbVie Company Press-Release  
  1. VENCLEXTA (venetoclax) [Package Insert]. North Chicago, Ill.: AbbVie Inc.
  2. Farrell A. Grant-Breakthrough Therapy Designation (CLL). Department of Health and Human Services. 2015:1–3.
  3. Farrell A. Grant-Breakthrough Therapy Designation (CLL). Department of Health and Human Services. 2015:1–3.
  4. Farrell A. Grant-Breakthrough Therapy Designation (AML). Department of Health and Human Services. 2016:1–3.
  5. Farrell A. Grant-Breakthrough Therapy Designation (AML). Department of Health and Human Services. 2017:1–3.
  6. Farrell A. Grant-Breakthrough Therapy Designation (CLL). Department of Health and Human Services. 2019:1–3.
  7. American Cancer Society (2018). Chronic Lymphocytic Leukemia (CLL). Available from: https://www.cancer.org/cancer/chronic-lymphocytic-leukemia.html. Accessed January, 2019.
  8. gov (2018). NCT02242942: A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare The Efficacy and Safety of A Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients With CLL and Coexisting Medical Conditions. Available from: https://clinicaltrials.gov/ct2/show/NCT02242942?term=NCT02242942&draw=2&rank=1. Accessed February, 2019.
  9. gov (2018). NCT02993523: A study of venetoclax in combination with azacytidine versus azacytidine in treatment naive subjects with acute myeloid leukemia who are ineligible for standard induction therapy. Available from: https://clinicaltrials.gov/ct2/show/NCT02993523?term=NCT02993523&draw=2&rank=1. Accessed January, 2019.
  10. gov (2018). NCT03069352: A study of venetoclax in combination with low dose cytarabine versus low dose cytarabine alone in treatment naive patients with acute myeloid leukemia who are ineligible for intensive chemotherapy. Available from: https://clinicaltrials.gov/ct2/show/NCT03069352?term=NCT03069352&draw=2&rank=1. Accessed January, 2019.
  11. gov (2018). NCT01794520: Study evaluating ABT-199 in subjects with relapsed or refractory Multiple Myeloma. Available from: https://clinicaltrials.gov/ct2/results?cond=NCT01794520&term=&cntry=&state=&city=&dist=1.Accessed January, 2019.
  12. gov (2018). NCT01328626: A Phase 1 study evaluating the safety and pharmacokinetics of ABT-199 in subjects with relapsed or refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=NCT01328626&cntry=&state=&city=&dist=. Accessed January, 2019.
  13. gov (2018). NCT02942290: A study evaluating venetoclax in combination with azacytidine in subjects with treatment-naive higher-risk myelodysplastic syndromes (MDS). Available from: https://clinicaltrials.gov/ct2/results?cond=&term=NCT02942290&cntry=&state=&city=&dist=. Accessed January, 2019.
  14. S. Food and Drug Administration (2016). News and Events: FDA approves new drug for chronic lymphocytic leukemia in patients with a specific chromosomal abnormality. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-chronic-lymphocytic-leukemia-patients-specific-chromosomal-abnormality. Accessed January, 2019.
  15. S. Food and Drug Administration (2018). Approved Drugs: FDA approves venetoclax in combination for AML in adults. Available from: https://www.fda.gov/drugs/fda-approves-venetoclax-combination-aml-adults. Accessed January, 2019.
  16. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019;380(23):2225–36. doi: 10.1056/NEJMoa1815281.
  17. Венклекста® (инструкция по медицинскому применению). Доступно по: https://grls.rosminzdrav.ru/Grls_View_vaspx?routingGuid=661ec394-1a55-48c0-b124-f64f5fd18951&t=. Ссылка активна на 28.02.2020.

License

Copyright (c) 2020 Clinical Oncohematology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.
2020-2

Downloads

Published

01.07.2025

Issue

Vol. 13 No. 2 (2020)
NEWS

How to Cite

AbbVie Company Press-Release. Clinical Oncohematology. Basic Research and Clinical Practice. 2025;13(2):235–237. doi:10.21320/.